Novogene specializes in the application of advanced molecular biotechnology and high-performance computing in the research fields of life science and human health. Established in March 2011, it strives to become a global leader in providing genetic science services and technology products. It has set up operations and laboratories in the United States, the United Kingdom, Netherlands, Germany, as well as in China, Singapore and Japan.
Novogene has served over 7,300 global customers, covering 90 countries and regions across 6 continents. By 2023, it has co-published and/or been acknowledged in more than 22,850 articles in Science Citation Index, with an accumulative impact factor of more than 148,250.
Novogene’s partners are worldwide and include more than 4,200 scientific research institutions and universities, more than 680 hospitals and over 2,400 pharmaceutical and agricultural enterprises. Currently, Novogene has obtained 356 software copyrights and 66 patents.